Listed

Eledon Pharmaceuticals, Inc.: Form 10-K for the period ended Dec 31, 2019

Filed with the SEC on Mar 17, 2020 and accepted by EDGAR at Mar 16, 2020, 20:46 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development12 months2019-01-01 to 2019-12-31$8.1mus-gaap:ResearchAndDevelopmentExpense
Operating income12 months2019-01-01 to 2019-12-31−$16.1mus-gaap:OperatingIncomeLoss
Net income12 months2019-01-01 to 2019-12-31−$16.0mus-gaap:NetIncomeLoss
Diluted EPS12 months2019-01-01 to 2019-12-31−$1.36us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow12 months2019-01-01 to 2019-12-31−$13.9mus-gaap:NetCashProvidedByUsedInOperatingActivities
Cash and equivalentsAt period end2019-12-31$8.8mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2019-12-31$10.0mus-gaap:AssetsCurrent
Total assetsAt period end2019-12-31$10.9mus-gaap:Assets
Current liabilitiesAt period end2019-12-31$1.3mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2019-12-31$1.5mus-gaap:Liabilities
Shareholders' equityAt period end2019-12-31$9.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001564590-20-011260. Last ingested by Listed: Nov 13, 2026, 16:16 ET. Listed shows no prices and gives no investment advice.